background
reliabl
sign
symptom
differenti
mycoplasma
pneumonia
mp
infect
communityacquir
pneumonia
cap
etiolog
addit
current
diagnost
test
reliabl
distinguish
mp
infect
carriag
previous
determin
measur
mpspecif
immunoglobulin
antibodysecret
cell
asc
enzymelink
immunospot
assay
allow
differenti
infect
carriag
use
new
diagnost
test
aim
identifi
clinic
laboratori
featur
associ
mp
infect
method
prospect
cohort
studi
children
year
age
cap
clinic
featur
biomark
compar
mpposit
neg
group
mannwhitney
u
test
fisher
exact
test
appropri
area
receiv
oper
characterist
curv
auc
differ
optim
threshold
determin
use
delong
test
youden
j
statist
respect
result
cap
patient
mpposit
mp
posit
statist
associ
older
age
median
vs
year
underli
diseas
famili
respiratori
symptom
prior
antibiot
treatment
prolong
prodrom
respiratori
symptom
fever
extrapulmonari
skin
manifest
lower
level
creactiv
protein
white
blood
cell
count
absolut
neutrophil
count
procalcitonin
pct
specif
pct
statist
associ
mp
infect
combin
age
year
auc
prodrom
fever
respiratori
symptom
day
auc
pct
auc
improv
diagnost
perform
auc
p
conclus
combin
clinic
featur
biomark
may
aid
physician
identifi
patient
high
risk
mp
cap
mycoplasma
pneumonia
mp
common
bacteri
caus
communityacquir
pneumonia
cap
children
substanti
challeng
differenti
infect
carriag
mp
current
diagnost
test
includ
polymeras
chain
reaction
pcr
upper
respiratori
tract
urt
specimen
serolog
reliabl
differenti
mp
infect
carriag
therefor
surpris
previou
studi
found
sign
symptom
differenti
mp
infect
cap
etiolog
potenti
mp
detect
misclassifi
infect
fact
carriag
mp
carriag
estim
occur
healthi
children
mp
infect
gener
mild
selflimit
patient
mp
cap
mostli
manag
primari
care
lack
cell
wall
make
mp
natur
resist
firstlin
empir
antibiot
cap
empir
macrolid
treatment
extens
use
cover
potenti
mp
infect
led
emerg
macrolideresist
mp
parallel
rise
macrolid
resist
respiratori
pathogen
therefor
challeng
diagnost
test
mp
limit
use
primari
care
set
essenti
determin
clinic
featur
biomark
aid
diagnosi
mp
infect
children
cap
recent
demonstr
prospect
cohort
studi
cap
children
measur
specif
peripher
blood
immunoglobulin
igm
antibodysecret
cell
asc
enzymelink
immunospot
elispot
assay
improv
diagnosi
mp
infect
cap
test
differenti
mp
infect
carriag
use
dataset
aim
identifi
clinic
featur
biomark
associ
mp
cap
infect
may
accur
identifi
measur
mpspecif
igm
asc
patient
enrol
may
april
univers
children
hospit
zurich
cap
clinic
defin
presenc
fever
tachypnea
accord
british
thorac
societi
bt
guidelin
elig
particip
inpati
outpati
age
year
cap
patient
year
age
exclud
reduc
probabl
viral
infect
highest
age
group
patient
hospitalacquir
pneumonia
cystic
fibrosi
chronic
lung
disord
exclud
asthma
known
primari
secondari
immunodefici
exclud
local
ethic
committe
approv
protocol
studi
number
written
inform
consent
obtain
parent
children
year
age
enrol
patient
investig
mp
pharyng
swab
sampl
specif
realtim
pcr
addit
consent
given
blood
sampl
collect
separ
peripher
blood
mononuclear
cell
pbmc
serum
serum
store
detail
elsewher
cap
patient
includ
studi
fresh
isol
hour
pbmc
avail
avoid
poor
elispot
assay
perform
test
presenc
mp
igm
asc
cap
patient
posit
mp
igm
asc
elispot
assay
result
consid
cap
caus
mp
mp
posit
mp
igm
asc
detect
patient
consid
cap
caus
anoth
etiolog
mp
neg
addit
investig
frequenc
mp
pcr
pharyng
swab
among
household
contact
avail
sampl
present
index
patient
studi
closur
pharyng
swab
sampl
kept
addit
test
streptococcu
pneumonia
sp
realtim
pcr
know
detect
sp
urt
like
colon
infect
fact
coinfect
sp
mp
uncommon
wherea
cocolon
may
common
anoth
viral
bacteri
respiratori
pathogen
test
use
eplex
respiratori
pathogen
panel
genmark
diagnost
carlsbad
california
previous
describ
addit
mp
serolog
perform
virionserion
germani
studi
test
result
avail
treat
clinician
demograph
epidemiolog
clinic
data
systemat
collect
use
standard
questionnair
full
recoveri
assess
month
enrol
chest
radiograph
order
clinic
reason
therefor
avail
patient
chest
radiograph
assess
radiologist
routin
clinic
care
radiolog
find
correspond
imag
retrospect
review
author
blind
clinic
inform
use
criteria
radiograph
pneumonia
blood
cell
count
creactiv
protein
crp
analysi
perform
part
routin
clinic
care
procalcitonin
pct
test
perform
retrospect
batch
analysi
result
avail
treat
physician
pct
level
measur
use
sensit
assay
detect
limit
ngml
pct
sensit
kryptor
thermoscientif
berlin
germani
nonparametr
mannwhitney
u
test
use
compar
continu
variabl
fisher
exact
test
compar
proport
mpposit
mpneg
group
calcul
area
receiv
oper
characterist
roc
curv
auc
clinic
featur
biomark
differenti
group
determin
mp
igm
asc
elispot
assay
refer
standard
consid
auc
adequ
discrimin
auc
differ
calcul
use
delong
test
miss
valu
remov
ignor
rocformula
best
biomark
threshold
defin
optim
cutoff
maxim
distanc
ident
diagon
line
roc
curv
accord
youden
j
statist
report
p
valu
statist
signific
defin
p
valu
data
analyz
use
r
softwar
environ
version
studi
period
cap
patient
enrol
mp
dna
detect
pcr
particip
enrol
popul
cap
patient
met
criteria
fresh
pbmc
avail
undergo
diagnost
test
mp
igm
asc
elispot
assay
includ
studi
mpposit
determin
detect
mp
igm
asc
detail
elsewher
mp
igm
ascposit
patient
also
mp
pcr
posit
igm
posit
howev
mp
pcr
also
posit
patient
mp
igm
asc
igm
neg
mp
igm
found
anoth
patient
mp
igm
asc
pcr
neg
chest
radiograph
perform
includ
cap
patient
whereof
met
criteria
radiograph
pneumonia
fever
detect
urt
sibl
mother
father
report
rti
symptom
sibl
mother
asymptomat
carrier
durat
rti
symptom
fever
prior
cap
diagnosi
longer
mpposit
median
iqr
day
mpneg
patient
iqr
day
p
symptom
sign
statist
differ
group
mpposit
patient
differ
mpneg
patient
consolid
interstiti
infiltr
pleural
effus
extrapulmonari
manifest
observ
mpposit
children
cap
vs
p
includ
dermatolog
neurolog
disord
tabl
inclus
mpposit
patient
treat
antibiot
vitro
activ
mp
hospit
rate
length
hospit
stay
similar
group
detail
characterist
hospit
ambulatori
mpposit
mpneg
patient
shown
supplementari
tabl
among
hospit
patient
mpposit
patient
like
oxygen
demand
extrapulmonari
manifest
poor
outcom
mpneg
patient
sequela
observ
b
patient
year
age
enrol
inclus
criteria
c
per
nation
immun
schedul
switzerland
chronic
lung
disord
exclud
asthma
part
exclus
criteria
e
asymptomat
carrier
mpposit
cap
famili
member
sibl
mother
mpneg
cap
famili
member
mother
f
accord
predict
rule
risk
mp
infect
children
cap
fischer
et
al
g
inclus
criteria
clinic
diagnosi
cap
fever
tachypnea
accord
british
thorac
societi
guidelin
h
radiograph
evid
pneumonia
part
inclus
criteria
routin
perform
includ
cap
patient
met
criteria
radiolog
pneumonia
hematolog
assess
togeth
pct
crp
analysi
mpposit
mpneg
cap
patient
shown
tabl
mpposit
cap
patient
lower
white
blood
cell
wbc
count
absolut
neutrophil
count
anc
pct
crp
valu
mpneg
patient
figur
differ
clinic
featur
biomark
may
attribut
anoth
pathogen
caus
subset
infect
therefor
pharyng
swab
sampl
test
studi
pathogen
two
pathogen
found
urt
mpposit
mpneg
patient
tabl
sp
equal
detect
cohort
exclus
found
mpneg
patient
respiratori
syncyti
viru
rsv
n
p
influenza
viru
n
parainfluenza
viru
n
coronaviru
n
viru
statist
associ
mp
posit
rhinoviru
adenoviru
bocaviru
equal
detect
cohort
thu
also
compar
clinic
featur
biomark
mpposit
patient
follow
subgroup
mpneg
patient
n
first
posit
rsv
n
viru
detect
urt
high
predict
valu
cap
etiolog
second
posit
abbrevi
anc
absolut
neutrophil
count
cap
communityacquir
pneumonia
ci
confid
interv
crp
creactiv
protein
iqr
interquartil
rang
mp
mycoplasma
pneumonia
na
avail
odd
ratio
pct
procalcitonin
wbc
white
blood
cell
agespecif
refer
valu
hematolog
defin
previous
describ
b
accord
admiss
crppct
ratio
risk
mp
infect
hospit
adult
cap
neeser
et
al
virus
rsv
n
awar
urt
detect
pathogen
rsv
may
relat
pneumonia
third
neg
virus
n
sp
detect
urt
addit
pleural
aspir
routin
clinic
care
howev
although
number
smaller
subanalysi
mpposit
cap
also
compar
subgroup
mpneg
cap
statist
associ
older
age
prolong
prodrom
respiratori
symptom
low
level
pct
supplementari
figur
supplementari
tabl
roc
analysi
perform
clinic
featur
biomark
associ
mpposit
cap
roc
curv
show
good
discrimin
abil
auc
differenti
group
age
auc
durat
prodrom
symptom
auc
pct
auc
crp
auc
figur
best
clinic
threshold
discrimin
mpposit
mpneg
patient
age
year
prodrom
fever
rti
symptom
durat
day
tabl
optim
biomark
threshold
pct
mgl
crp
l
wbc
count
l
anc
assess
mpposit
cap
posit
likelihood
ratio
highest
age
year
tabl
evalu
clinic
featur
biomark
diagnos
mp
infect
within
welldefin
cohort
ambulatori
hospit
children
cap
mp
infect
diagnos
mp
igm
asc
elispot
assay
allow
differenti
mp
infect
carriag
diagnos
mp
caus
cap
earli
stage
import
avoid
ineffect
firstlin
empir
antibiot
evalu
target
treatment
mp
sever
case
sever
score
ratio
algorithm
predict
rule
report
diagnos
mp
infect
basi
clinic
featur
howev
previou
studi
found
reliabl
sign
symptom
differenti
mp
infect
cap
etiolog
potenti
mp
infect
misclassifi
infect
carriag
recent
demonstr
mp
igm
asc
elispot
assay
differenti
mp
infect
carriag
mp
dna
andor
igm
also
detect
healthi
control
children
n
test
neg
mp
igm
asc
elispot
assay
notabl
high
mp
detect
rate
cap
patient
studi
may
relat
inclus
age
year
mp
frequent
detect
coincid
mp
epidem
europ
studi
period
preval
estim
import
translat
diagnost
studi
find
clinic
practic
take
bay
theorem
account
posttest
probabl
diseas
presenc
higher
given
higher
pretest
probabl
preval
proper
implement
new
diagnost
test
clinic
practic
therefor
necessari
test
assess
context
diagnost
inform
avail
time
point
test
abl
corrobor
previou
studi
find
mpposit
cap
manifest
predominantli
schoolag
children
year
children
present
prodrom
fever
respiratori
symptom
day
significantli
longer
compar
cap
caus
etiolog
symptom
sign
well
radiograph
find
differenti
mpposit
mpneg
cap
data
present
differ
proport
determin
fisher
exact
test
p
valu
indic
bold
pharyng
sampl
test
patient
realtim
polymeras
chain
reaction
pcr
mp
sp
bacteri
viral
pathogen
eplex
respiratori
panel
extrapulmonari
manifest
predominantli
skin
disord
statist
associ
mpposit
cap
studi
presenc
significantli
increas
probabl
underli
mp
infect
may
also
true
presenc
rti
within
famili
mpposit
cap
patient
observ
frequent
rti
symptom
mp
detect
member
famili
support
previou
data
mp
spread
among
person
close
contact
famili
transmiss
mp
mp
infect
mild
selflimit
case
manifest
predominantli
previous
healthi
children
studi
onethird
mpposit
cap
patient
treat
antibiot
vitro
activ
mp
children
fulli
recov
bt
guidelin
advis
macrolid
antibiot
may
ad
age
case
sever
diseas
respons
firstlin
empir
treatment
prior
antibiot
treatment
associ
mp
cap
includ
treatment
antibiot
case
support
patient
respond
antibiot
mp
cap
consid
find
statist
differ
fever
durat
follow
cap
diagnosi
hospit
length
stay
recoveri
followup
mpposit
patient
receiv
antibiot
mp
data
shown
find
support
need
futur
intervent
studi
assess
effect
antibiot
mp
cap
studi
demonstr
mpposit
cap
biomark
level
pct
crp
wbc
count
anc
statist
lower
compar
mpneg
cap
despit
limit
number
threshold
optim
cutoff
maxim
distanc
ident
diagon
line
receiv
oper
characterist
curv
figur
accord
youden
j
statist
use
coord
function
r
softwar
environ
version
abbrevi
anc
absolut
neutrophil
count
auc
area
receiv
oper
characterist
curv
ci
confid
interv
crp
creactiv
protein
lr
likelihood
ratio
na
avail
pct
procalcitonin
rti
respiratori
tract
infect
wbc
white
blood
cell
even
true
pct
crp
mpposit
cap
comparison
viral
cap
rsv
subgroup
mpneg
cap
similar
trend
observ
previou
cap
studi
crp
wbc
count
anc
recent
pct
median
level
cap
consid
caus
mp
studi
conflict
result
suggest
higher
pct
level
associ
mp
may
hamper
diagnost
pct
cutoff
reach
best
discriminatori
power
differenti
mpposit
mpneg
children
cap
support
previou
studi
mpposit
patient
pct
level
cutoff
studi
sever
limit
first
though
sampl
perform
relev
popul
clinic
cap
studi
popul
small
repres
conveni
sampl
observ
studi
rule
unintend
select
occur
howev
even
though
sampl
size
small
predict
scope
studi
describ
risk
factor
mp
infect
second
mild
case
may
refer
tertiari
center
third
studi
enrol
children
year
age
reduc
probabl
viral
infect
howev
younger
children
mp
infect
may
like
rti
cap
conclus
improv
diagnost
help
identifi
clinic
featur
biomark
may
predict
mp
cap
children
age
year
underli
diseas
famili
rti
prior
antibiot
treatment
prodrom
respiratori
symptom
fever
day
well
extrapulmonari
skin
manifest
biomark
show
differ
mpposit
mpneg
patient
mp
posit
associ
low
level
crp
wbc
count
anc
pct
particularli
pct
cutoff
howev
studi
size
small
even
best
combin
clinic
featur
biomark
may
reliabl
enough
use
diagnost
data
support
combin
clinic
featur
biomark
may
help
physician
identifi
patient
high
risk
mp
cap
warrant
investig
larger
cohort
children
mp
infect
supplementari
materi
avail
clinic
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
